Date: 2015-03-24
Type of
information: Presentation of results at a congress
phase: 3
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting, in Philadelphia, Pennsylvania, April 18-22, 2015
Company: Erytech Pharma (France)
Product: Ery-asp®/Graspa® (eryaspase - L-asparaginase loaded erythrocytes)
Action
mechanism:
- enzyme. Ery-asp®/Graspa® is a new formulation of L-asparaginase encapsulated inside donor-derived red blood cells through Erytech’s proprietary ERYCAPS technology platform. The enzyme degrades asparagine, an amino acid that is essential for the tumor cells to grow and multiply, which starves and eventually kills the cancer cells.
Disease: acute lymphoblastic leukemia
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On March 24, 2015, Erytech Pharma announced the upcoming presentation of three abstracts, at the American Association for Cancer Research (AACR) taking place in Philadelphia, PA, USA from 18 to 22 April 2015. Details for the three posters are as follows:
- A phase III, multicenter, randomized study evaluating the efficacy and safety of erythrocyte encapsulated l-asparginase (ERY001) versus native l-asparaginase (L-asp) in combination with COOPRALL regimen with first relapse of acute lymphoblastic leukemia (Abstract # CT113)
- Low asparagine synthetase expression and in vitro sensitivity highlights l-asparginase potential for the treatment of aggressive lymphomas (Abstract # 5369)
- Methioninase loaded erythrocytes: a promising drug for l-methionine restriction therapy in cancer (Abstract # 5330).
Is
general: Yes
